CSL 112

Drug / Medication

A recombinant HDL particle containing ApoA1, currently in clinical development. It's designed to promote cholesterol efflux and is being tested in acute coronary syndrome settings to see if it can reduce cardiovascular events.

Mentioned in 1 video

Videos Mentioning CSL 112

240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.

240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.

Peter Attia MD

A recombinant HDL particle containing ApoA1, currently in clinical development. It's designed to promote cholesterol efflux and is being tested in acute coronary syndrome settings to see if it can reduce cardiovascular events.